FdaApplication
NDA 213051
Identifiers
- fda_app_no: NDA213051
Properties
| Property | Value |
|---|---|
| applicant_name | NOVO NORDISK INC |
| application_type | NDA |
| approval_date | 2019-09-20 |
Products (6)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| OZEMPIC | SEMAGLUTIDE | 1.5MG | TABLET;ORAL |
| OZEMPIC | SEMAGLUTIDE | 4MG | TABLET;ORAL |
| OZEMPIC | SEMAGLUTIDE | 9MG | TABLET;ORAL |
| RYBELSUS | SEMAGLUTIDE | 14MG | TABLET;ORAL |
| RYBELSUS | SEMAGLUTIDE | 7MG | TABLET;ORAL |
| RYBELSUS | SEMAGLUTIDE | 3MG | TABLET;ORAL |
6 products